ReviewDigestive diseases (Basel, Switzerland)2016
Methotrexate for Inflammatory Bowel Diseases - New Developments.
Review in Digestive diseases (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Phase IV Metabolism: Gut Microbial Metabolism of Common Gastrointestinal Drugs.Gastroenterology clinics of North America · 2025Review
- Natural Product-based Therapies for Inflammatory Bowel Disease: Targeting Key Signaling Pathways.Mini reviews in medicinal chemistry · 2025Review
- Systemic inhibition ofbioRxiv : the preprint server for biology · 2024Article
- Efficacy of Methotrexate and Anti-TNF Combination Therapy in Adults with Refractory Crohn's Disease.Middle East journal of digestive diseases · 2024Article
- The Prospective Effect of Green Tea versus Pomegranate Peels Extracts on Submandibular Salivary Glands of Albino Rats after Methotrexate Administration (Histological and Immunohistochemical Study).International journal of dentistry · 2024Article
- Treatment Effects of Natural Products on Inflammatory Bowel Disease In Vivo and Their Mechanisms: Based on Animal Experiments.Nutrients · 2023Review
- Inflammatory Bowel Disease-related Spondyloarthritis: The Last Unexplored Territory of Rheumatology.Mediterranean journal of rheumatology · 2022Review
- Analysis of the Therapeutic Effect of Changyanning on Intestinal Flora in Inflammatory Bowel Disease.Contrast media & molecular imaging · 2022Article
- Protective effects of apigenin on altered lipid peroxidation, inflammation, and antioxidant factors in methotrexate-induced hepatotoxicity.Naunyn-Schmiedeberg's archives of pharmacology · 2021Article
- Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders.Therapeutic advances in neurological disorders · 2021Review
- Targeting immunometabolism as an anti-inflammatory strategy.Cell research · 2020Review
- The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients.Cancer management and research · 2018Article
- Investigator-Initiated IBD Trials in the United States: Facts, Obstacles, and Answers.Inflammatory bowel diseases · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Methotrexate (MTX) is an established therapy for patients with steroid-dependent Crohn's disease (CD). MTX is also frequently used in combination with anti-TNF agents to suppress anti-drug antibody formation. It has been suggested in the past that MTX lacks any clinical effectiveness in patients with ulcerative colitis (UC); however, newer data at least partially contradict this assumption. The following review will discuss recent data for the use of MTX in CD, UC and in combination with anti-TNF agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.